Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. SciClone Pharmaceuticals (Holdings) Limited
  6. News
  7. Summary
    6600   KYG4271B1023

SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

(6600)
  Report
Delayed Hong Kong Stock Exchange  -  05/25 04:08:04 am EDT
8.500 HKD   -0.82%
05/20SciClone Pharma Updates Share Buyback Plan
MT
05/19Sciclone Pharmaceuticals Limited Approves Final Dividend for the Year Ended December 31, 2021
CI
04/19China Accepts SciClone Pharma's Clinical Trial Application for Neuroblastoma Immunotherapy
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
05/20SciClone Pharma Updates Share Buyback Plan
MT
05/19Sciclone Pharmaceuticals Limited Approves Final Dividend for the Year Ended December 31..
CI
04/19China Accepts SciClone Pharma's Clinical Trial Application for Neuroblastoma Immunother..
MT
03/29SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 67,787,426 shares..
CI
03/25SciClone Pharma's Per-Share Earnings Slip in 2021
MT
03/24SciClone Pharma Launches Buyback Program; Shares Rally 14%
MT
03/24SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended Decem..
CI
03/24Sciclone Pharmaceuticals Limited Recommends Final Dividend for the Year Ended December ..
CI
02/24SciClone Pharma Sees Higher Profit in 2021
MT
2021SciClone Pharmaceuticals Grants Nearly 4 Million Share Options
MT
2021SCICLONE PHARMACEUTICALS LIMITED(SEH : 6600) added to S&P Global BMI Index
CI
2021SCICLONE PHARMACEUTICALS : Wins License for Preclinical Miniature Solid Tumor Inhibitor
MT
2021SCICLONE PHARMACEUTICALS : Gets Priority Review for Neuroblastoma Treatment in China
MT
2021NMPA Grants Priority Review to BLA of DANYELZA®
CI
2021610,329,800 Ordinary Shares of SciClone Pharmaceuticals Limited are subject to a Lock-U..
CI
More most relevant news
All news about SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
05/20SciClone Pharma Updates Share Buyback Plan
MT
05/19Sciclone Pharmaceuticals Limited Approves Final Dividend for the Year Ended December 31..
CI
04/19China Accepts SciClone Pharma's Clinical Trial Application for Neuroblastoma Immunother..
MT
03/29SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 67,787,426 shares..
CI
03/25SciClone Pharma's Per-Share Earnings Slip in 2021
MT
03/24SciClone Pharma Launches Buyback Program; Shares Rally 14%
MT
03/24SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended Decem..
CI
03/24Sciclone Pharmaceuticals Limited Recommends Final Dividend for the Year Ended December ..
CI
02/24SciClone Pharma Sees Higher Profit in 2021
MT
2021SciClone Pharmaceuticals Grants Nearly 4 Million Share Options
MT
More news
News in other languages on SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
05/20SciClone Pharma met à jour son plan de rachat d'actions
05/19Sciclone Pharmaceuticals (Holdings) Limited approuve le dividende final pour l'année se..
04/19La Chine accepte la demande d'essai clinique de SciClone Pharma pour l'immunothérapie d..
03/29SCICLONE PHARMACEUTICALS (HOLDINGS) : 6600) lance un plan de rachat d'actions pour 67 787..
03/25Le bénéfice par action de SciClone Pharma dégringole en 2021
03/24SciClone Pharma lance un programme de rachat ; les actions augmentent de 14 %.
03/24SciClone Pharmaceuticals (Holdings) Limited annonce ses résultats pour l'année complète..
03/24Sciclone Pharmaceuticals (Holdings) Limited recommande un dividende final pour l'exerci..
02/24SciClone Pharma prévoit une hausse des bénéfices en 2021
2021La Chine accepte la demande de licence de produits biologiques de SciClone Pharma pour ..
More news
Press releases
2021Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA (naxitamab-gqgk) in..
AQ
2021Y MABS THERAPEUTICS : mAbs Announces NMPA Submission of BLA for DANELZA (naxitamab-gqgk) i..
AQ
2021SCICLONE PHARMACEUTICALS : Form of proxy for the annual general meeting to be held on wedn..
PU
2021SCICLONE PHARMACEUTICALS : Proposed election and re-election of directors and proposed gra..
PU
2021SCICLONE PHARMACEUTICALS : Voluntary Announcement - Official Initiation of the Clinical St..
PU
More press releases
Upcoming sector events
07/26/22BIOGEN INC. : Interim 2022 Earnings Release (Projected)
08/16/22SAMSUNG BIOLOGICS CO.,LTD. : Interim 2022 Earnings Release (Projected)
08/17/22CSL LIMITED : FY 2022 Earnings Release
08/22/22WUXI BIOLOGICS (CAYMAN) INC. : Interim 2022 Earnings Release (Projected)
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Biopharmaceuticals